The AquaHeart system allows for a so called „single shot“, ultra short insulation of each of the pulmonary veins.
Atrial Fibrillation is a potentially deadly condition, yet only 10% of patients receive curative treatment today. At AquaHeart, we are on a mission to change that. Our groundbreaking high-energy, short-duration, single-shot Pulmonary Vein Isolation technology is paving the way for accessible treatment on a global scale.
By developing a solution that can be applied faster, safer, and more easily, we are addressing a large unmet need of untreated Atrial Fibrillation patients. With AquaHeart, heart ablation is no longer limited to a select few—it is now within reach for all patients and interventional cardiologist.
Recognized as a Top 10 Cardiovascular Solution Provider 2023
April 2023, AquaHeart was honored to be listed as a top 10 solution provider in the cardiovascular space. Our CEO, Dr. Holger Friedrich, highlighted the remarkable benefits of the AquaHeart system in an article, solidifying our position as leaders in the field of Pulmonary Vein Isolation. We are proud to be driving advancements that will reshape the landscape of cardiac care.